Tavalisse - (100,150 mg ; Tablet, Oral)

Generic Name	Fostamatinib Disodium	Innovator	Rigel Pharms
Dosage	100,150 mg ; Tablet, Oral	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****** ******	*** / *********	*** **, ****	*******	********* ********	*** ****** *** ****

Chronology Of Events